1. Home
  2. VGI vs RVPH Comparison

VGI vs RVPH Comparison

Compare VGI & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VGI
  • RVPH
  • Stock Information
  • Founded
  • VGI 2012
  • RVPH 2006
  • Country
  • VGI United States
  • RVPH United States
  • Employees
  • VGI N/A
  • RVPH N/A
  • Industry
  • VGI Investment Managers
  • RVPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • VGI Finance
  • RVPH Health Care
  • Exchange
  • VGI Nasdaq
  • RVPH Nasdaq
  • Market Cap
  • VGI N/A
  • RVPH 32.8M
  • IPO Year
  • VGI N/A
  • RVPH N/A
  • Fundamental
  • Price
  • VGI $7.88
  • RVPH $0.36
  • Analyst Decision
  • VGI
  • RVPH Strong Buy
  • Analyst Count
  • VGI 0
  • RVPH 5
  • Target Price
  • VGI N/A
  • RVPH $9.00
  • AVG Volume (30 Days)
  • VGI 46.0K
  • RVPH 2.4M
  • Earning Date
  • VGI 01-01-0001
  • RVPH 08-13-2025
  • Dividend Yield
  • VGI 12.66%
  • RVPH N/A
  • EPS Growth
  • VGI N/A
  • RVPH N/A
  • EPS
  • VGI N/A
  • RVPH N/A
  • Revenue
  • VGI N/A
  • RVPH N/A
  • Revenue This Year
  • VGI N/A
  • RVPH N/A
  • Revenue Next Year
  • VGI N/A
  • RVPH N/A
  • P/E Ratio
  • VGI N/A
  • RVPH N/A
  • Revenue Growth
  • VGI N/A
  • RVPH N/A
  • 52 Week Low
  • VGI $6.68
  • RVPH $0.30
  • 52 Week High
  • VGI $7.99
  • RVPH $4.28
  • Technical
  • Relative Strength Index (RSI)
  • VGI 67.63
  • RVPH 29.52
  • Support Level
  • VGI $7.50
  • RVPH $0.30
  • Resistance Level
  • VGI $7.73
  • RVPH $0.83
  • Average True Range (ATR)
  • VGI 0.06
  • RVPH 0.07
  • MACD
  • VGI 0.01
  • RVPH -0.04
  • Stochastic Oscillator
  • VGI 100.00
  • RVPH 11.25

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: